Biomarker · Gene alteration

MET exon 14 skipping

MET alterations causing exon 14 skipping detected by RNA- or DNA-based sequencing; used as a predictive marker for MET tyrosine kinase inhibitors in non-small cell lung cancer.

CI-BIO-00000020MET graph →NCIt C131179

Also calledMETex14 · MET exon 14 alteration · METΔ14

Derived

Associated cancers (3)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Adenocarcinoma	5	5	—	—	0 / 0 / 5 / 0 / 0
Lung Non-Small Cell Carcinoma	4	4	—	—	1 / 2 / 1 / 0 / 0
Malignant Neoplasm	2	2	—	—	0 / 0 / 0 / 2 / 0

Derived

Drugs with predictive evidence (3)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CrizotinibSmall Molecule	8	8	—	B	8 / 0	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm
CapmatinibSmall Molecule	3	3	—	A	3 / 0	Lung Adenocarcinoma

Curated evidence

Predictive evidence items (12)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–12 of 12 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MET Exon 14 Skipping Mutation12
Capmatinib

Regulatory

Approvals mentioning the linked drugs (26)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfda

Clinical trials

Active trials (24)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 10 recruiting · 11 active phase 3 · 91 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–24 of 24 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05488314	A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer(METalmark)	active not recruiting	Phase 1 / Phase 2

Literature

Linked publications (8)

Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–8 of 8 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
· Cancer Discov · 2015 · PMID 25971939 · validated civic_curation pubmed
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
· J Clin Oncol · 2016 · PMID 26729443 · validated civic_curation pubmed
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Capmatinib	US FDA	—	Efficacy supplement 2022-08-10 (see label)	approved	Aug 10, 2022	openfda
Capmatinib	US FDA	Lung Non-Small Cell Carcinoma	TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.	approved	May 6, 2020	openfda
Crizotinib	US FDA	Anaplastic Large Cell Lymphoma	pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.	approved	Sep 7, 2023	openfda
Crizotinib	US FDA	—	XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.	approved	Sep 7, 2023	openfda
Crizotinib	US FDA	—	Efficacy supplement 2023-09-07 (see label)	approved	Sep 7, 2023	openfda
Crizotinib	US FDA	Anaplastic Large Cell Lymphoma	o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.	approved	Sep 7, 2023	openfda
Crizotinib	US FDA	—	Efficacy supplement 2022-07-14 (see label)	approved	Jul 14, 2022	openfda
Crizotinib	US FDA	—	Efficacy supplement 2021-01-14 (see label)	approved	Jan 14, 2021	openfda
Crizotinib	US FDA	—	Efficacy supplement 2018-11-30 (see label)	approved	Nov 30, 2018	openfda
Crizotinib	US FDA	—	Efficacy supplement 2017-04-28 (see label)	approved	Apr 28, 2017	openfda
Crizotinib	US FDA	—	Efficacy supplement 2016-03-11 (see label)	approved	Mar 11, 2016	openfda
Crizotinib	US FDA	—	Efficacy supplement 2015-09-14 (see label)	approved	Sep 14, 2015	openfda
Crizotinib	US FDA	—	Efficacy supplement 2013-11-20 (see label)	approved	Nov 20, 2013	openfda
Crizotinib	US FDA	Anaplastic Large Cell Lymphoma	pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.	approved	Aug 26, 2011	openfda
Crizotinib	US FDA	—	XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.	approved	Aug 26, 2011	openfda
Crizotinib	US FDA	Anaplastic Large Cell Lymphoma	o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.	approved	Aug 26, 2011	openfda
Tepotinib	US FDA	—	Efficacy supplement 2024-02-15 (see label)	approved	Feb 15, 2024	openfda
Tepotinib	US FDA	Lung Non-Small Cell Carcinoma	TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. ( 1 )	approved	Feb 3, 2021	openfda